Navigation Links
PBS-Bio uncovers how Unibioscreen drug kills cancer
Date:3/9/2011

MESA, Ariz. March 8, 2011 Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

Previous studies have shown that over-activity of a gene known as MCL1 can cause cancer cells to grow out of control. PBS-Bio, which is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off the gene and induces apoptosis, the cancer cell's normal process of cellular death.

"It's a very nice candidate drug," said Dr. Michael Bittner, a biologist and Principal Investigator of the PBS-Bio technology. Dr. Bittner said UNBS1450 is effective against MCL1 in very low dosages, which means it could potentially be delivered to patients with minimal side effects and low toxicity. MCL1 is prevalent in leukemia, non-small-cell lung cancer, as well as cancers of the prostate and pancreas.

"The presence of MCL1 can be used as a stratification, or predictive, biomarker to help determine which cancer patients are most likely to respond to UNBS1450," said Dr. Edward Smith, co-founder and CEO of PBS-Bio. This would be particularly beneficial, Dr. Smith said, in selecting patients to participate in clinical trials of UNBS1450, and ultimately in helping physicians decide who should be placed on the drug once it is approved for general use.

Steve Weitman, Chief Medical Officer for Unibioscreen, based in Brussels, Belgium, said Unibioscreen has high hopes for the drug UNBS1450.

"Thanks to the critical assistance we received from PBS-Bio, we at Unibioscreen feel confident now that we have a potential biomarker that can be used to facilitate the development of UNBS1450," Weitman said.

In October, Unibioscreen announced it had entered into an agreement with PBS-Bio to get a more in depth understanding of the mechanisms involved in UNBS1450 as a means of optimizing cancer-patient treatment.

To jump-start drug development, PBS-Bio's analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways the so-called mechanisms of action.

UNBS1450 has been in Phase I clinical trials at hospitals in Belgium and the Netherlands. The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of a plant called Calotropis procera. Pre-clinical tests showed that UNBS1450 is very effective against various tumor types with no adverse side effects.


'/>"/>

Contact: Dr. Edward Smith
edsmith@pbs-bio.com
602-418-9300
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen partner, PBS-Bio, makes first breakthrough drug analysis
2. Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety
3. New Research Uncovers Elusive Target of Antifungal Agent
4. Purdue-IU team uncovers potential prostate cancer marker
5. Research uncovers extensive natural recovery after spinal cord injury
6. UCLA team uncovers mechanism behind organ transplant rejection
7. Quest for designer bacteria uncovers a Spy
8. Research uncovers a secret society connecting through the Internet
9. Research Uncovers Clue to SIDS
10. New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman
11. Cognitive Skills May Shrink With Tamoxifen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... NEW YORK, NY (PRWEB) , ... May 23, ... ... decision makers in the pharmaceutical and medical device sectors, today announced the winners ... • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National Council on ... to announce the organization’s Certified Strength Coach credential has earned accreditation from the ... program validates the competency of qualified candidates for jobs in the Strength and ...
(Date:5/23/2017)... Las Vegas, NV (PRWEB) , ... May 23, ... ... with Significance Dental Specialists, are educating patients on peri-implantitis in Las ... new patients to receive a custom gum disease consultation and leading care for ...
(Date:5/23/2017)... ... , ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications ... Connected Health and IoT: Technology Innovators and Disruption , the workshop is part of ... research and consulting firm specializing in emerging consumer technology products and services. , ...
(Date:5/23/2017)... Horeb, WI (PRWEB) , ... May 23, 2017 , ... ... invited to call Dr. Angela Cotey’s practice to schedule an appointment, with or without ... services, and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative to ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... FLINT, Mich. , May 8, 2017  Diplomat ... WRB Communications, Inc. ("WRB"), a health care ... . WRB specializes in relationship management ... organizations. WRB will ... of Diplomat,s commercialization support services for manufacturers, biotech firms, ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. ... add approximately 100,000 square feet to its Welch Allyn ... 2016 its commitment to bring more than 100 new ... where Welch Allyn has maintained a significant presence for ... accommodate these new positions, a large portion of which ...
(Date:5/4/2017)... 2017 Clarius Mobile Health, a digital ... scanners this week at the American Congress of ... San Diego, CA from ... the perfect tool for clinicians to easily confirm ... evaluate pregnancy-related complications like ectopic pregnancy and placenta ...
Breaking Medicine Technology: